Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheau-Feng Hwang

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Taiwanese Journal of Obstetrics & Gynecology|March 2, 2016
Clinical parameters associated with absence of endocervical/transformation zone component in conventional cervical Papanicolaou smearsLou Sun, Peng-Hui Wang, Chen-Hui Lee, et al.
Journal of Clinical Medicine|January 23, 2024
Maintenance Chemotherapy in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer after Second-Line ChemotherapyYen-Fu Chen, Shih-Tien Hsu, Sheau-Feng Hwang, et al.
Frontiers in Oncology|June 6, 2022
Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian CancerJo-Ni Hung, Shih-Tien Hsu, Lou Sun, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 28, 2019
Do-not-resuscitate status is correlated with the prescribed use of systemic strong opioid analgesics in patients with terminal cancer: an observational studyChun-Li Wang, Chia-Yen Lin, Chun-Che Huang, et al.
BMC Medicine|February 21, 2025
A retrospective study evaluating the effect of trastuzumab addition to carboplatin/paclitaxel on overall survival in patients with advanced-stage HER2/neu-overexpressing uterine serous carcinoma or carcinosarcomaTing-Fang Lu, Lou Sun, Yu-Hsiang Shih, et al.
BMC Medicine|March 15, 2025
Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancerShao-Jing Wang, Lou Sun, Yu-Hsiang Shih, et al.
Journal of Clinical Medicine|October 16, 2024
Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus PaclitaxelShao-Jing Wang, Hsin-Hua Chen, Lou Sun, et al.
Journal of Clinical Medicine|January 21, 2023
Improved Progression-Free Survival Associated with Tumor-Infiltrating Lymphocytes in High-Grade Endometrial CancerChun-Ting Fan, Shih-Tien Hsu, Lou Sun, et al.
Frontiers in Oncology|December 13, 2023
Efficacy and toxicities of doxorubicin plus ifosfamide in the second-line treatment of uterine leiomyosarcomaSzu-Yun Niu, Lou Sun, Shih-Tien Hsu, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Taiwanese Journal of Obstetrics & Gynecology|March 2, 2016
Clinical parameters associated with absence of endocervical/transformation zone component in conventional cervical Papanicolaou smearsLou Sun, Peng-Hui Wang, Chen-Hui Lee, et al.
Journal of Clinical Medicine|January 23, 2024
Maintenance Chemotherapy in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer after Second-Line ChemotherapyYen-Fu Chen, Shih-Tien Hsu, Sheau-Feng Hwang, et al.
Frontiers in Oncology|June 6, 2022
Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian CancerJo-Ni Hung, Shih-Tien Hsu, Lou Sun, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 28, 2019
Do-not-resuscitate status is correlated with the prescribed use of systemic strong opioid analgesics in patients with terminal cancer: an observational studyChun-Li Wang, Chia-Yen Lin, Chun-Che Huang, et al.
BMC Medicine|February 21, 2025
A retrospective study evaluating the effect of trastuzumab addition to carboplatin/paclitaxel on overall survival in patients with advanced-stage HER2/neu-overexpressing uterine serous carcinoma or carcinosarcomaTing-Fang Lu, Lou Sun, Yu-Hsiang Shih, et al.
BMC Medicine|March 15, 2025
Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancerShao-Jing Wang, Lou Sun, Yu-Hsiang Shih, et al.
Journal of Clinical Medicine|October 16, 2024
Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus PaclitaxelShao-Jing Wang, Hsin-Hua Chen, Lou Sun, et al.
Journal of Clinical Medicine|January 21, 2023
Improved Progression-Free Survival Associated with Tumor-Infiltrating Lymphocytes in High-Grade Endometrial CancerChun-Ting Fan, Shih-Tien Hsu, Lou Sun, et al.
Frontiers in Oncology|December 13, 2023
Efficacy and toxicities of doxorubicin plus ifosfamide in the second-line treatment of uterine leiomyosarcomaSzu-Yun Niu, Lou Sun, Shih-Tien Hsu, et al.
Pageof 2